Goldman Sachs Group Inc Atai Life Sciences N.V. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 98,641 shares of ATAI stock, worth $188,404. This represents 0.0% of its overall portfolio holdings.
Number of Shares
98,641
Previous 98,641
-0.0%
Holding current value
$188,404
Previous $134,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ATAI
# of Institutions
98Shares Held
23.7MCall Options Held
351KPut Options Held
170K-
Ubs Group Ag5.54MShares$10.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.29MShares$6.29 Million0.0% of portfolio
-
Pale Fire Capital Se Prague, 2N2.59MShares$4.95 Million0.42% of portfolio
-
Davidson Kempner Capital Management LP New York, NY1.41MShares$2.7 Million0.07% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$2.5 Million0.0% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $317M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...